Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT02859480

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02859480
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02859480. Randomized; no masking; primary purpose treatment. Start 2015-09 (registry gives no type); primary completion 2019-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
Acronym
ROSUVA-30
Condition
Coronary Disease
Condition
Cardiovascular Diseases
Intervention (Drug)
Rosuvastatin 5mg
Intervention (Drug)
Rosuvastatin 20mg
Lead sponsor
Korea University Anam Hospital (class: other)
Collaborator
Samjin Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02859480
Content hash
784781d0d6d4858b2266eadb492fd40ea3e3890b843676bfc22b110b9e4f3828